Get started
Work

DNA Methylation–Derived Immune Cell Profiles, CpG Markers of Inflammation, and Pancreatic Cancer Risk

Year: 2020
Type: article
Abstract: Background: Pancreatic cancer is projected to become the second most common cause of cancer-related death over the next 5 years. Because inflammation is thought to be a common trajectory for disease initiation, we sought to prospectively characterize immune profiles using DNA methylation markers and examine DNA methylation levels previously linked to inflammation biomarkers to evaluate whether these immune markers play a key role in pancreatic cancer. Methods: In a nested case–control study pooling three U.S. prospective cohort studies, DNA methylation was measured in prediagnostic leukocytes of incident pancreatic cancer cases and matched controls using the Illumina MethylationEPIC array. Differentially methylated regions were used to predict immune cell types, and CpGs previously associated with inflammatory biomarkers were selected for the analysis. DNA methylation data from a retrospective case–control study conducted in Spain (PanGenEU) was used for independent replication. Results: Immune cell proportions and ratio of cell proportions were not associated with pancreatic cancer risk in the nested case–control study. Methylation extent of CpGs residing in or near gene MNDA was significantly associated with pancreatic cancer risk in the nested case–control study and replicated in PanGenEU. Methylation level of a promoter CpG of gene PIM-1 was associated with survival in both studies. Conclusions: Using a targeted approach, we identified several CpGs that may play a role in pancreatic carcinogenesis in two large, independent studies with distinct study designs. Impact: These findings could provide insight into critical pathways that may help identify new markers of early disease and survival.
DOI: 10.1158/1055-9965.epi-20-0378
Authors: Dominique S. Michaud, Mengyuan Ruan, Devin C. Koestler, Lola Alonso, Esther Molina-Montes, Dong Pei, Carmen J. Marsit, Immaculata De Vivo, Núria Malats, Karl T. Kelsey
Institutions: Tufts University, Brown University, University of Kansas, The University of Kansas Cancer Center, University of Kansas Medical Center, Spanish National Cancer Research Centre, Centro de Investigación Biomédica en Red de Cáncer, Emory University, Brigham and Women's Hospital, Harvard University
Language: English
Open Access status: green
Funders: Kansas IDeA Network of Biomedical Research Excellence, European Cooperation in Science and Technology, National Institutes of Health, Instituto de Salud Carlos III, National Cancer Institute, National Institute of General Medical Sciences, FP7 Health
Awards: G1044543648, G1061377615, G1490553279, G178371107, G2147007994, G2222599731, G2315164337, G2343777156, G2588752297, G2620658983, G2921881625, Prospective immune profiling using methylation markers and pancreatic cancer risk, Psychological stress, associate biologic mediators, and ovarian cancer risk, Construcción y validación de modelos de predicción del riesgo para el cáncer de páncreas. Aplicación de un enfoque multi-ómico, G7301351283, G9000136728, G9000151747, Kansas IDeA Network of Biomedical Research Excellence 5, The Kansas Institute for Precision Medicine
OpenAlex ID: W3027393908
FWCI: 0.649
Cites: 25
Cited by: 14
Related to: 10